Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
AMER SOC HEMATOLOGY
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
Açıklama
Anahtar Kelimeler
Hematology
Kaynak
BLOOD
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
144
Sayı
Künye
Beksac, M., Garcia, E. G., Delimpasi, S., Robak, P., Karunanithi, K., De Arriba, F., ... & Dimopoulos, M. A. (2024). Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide. Blood, 144, 4731.
